Rosuvastatin: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
* Major Indication: Hyperlipidemia & High Cholesterol (Hypercholesterolemia)<br /> | * Major Indication: Hyperlipidemia & High Cholesterol (Hypercholesterolemia)<br /> | ||
* Drug Class: [[HMGR]] Inhibitor or Statin | * Drug Class: [[HMGR]] Inhibitor or Statin | ||
* Date of FDA Approval: 2003 <br /> | * Date of FDA Approval (Patent Expiration): 2003 (2016)<br /> | ||
* 2009 Sales: $4.5 Billion <ref>http://www.reuters.com/article/idUSN2223558720100222</ref> | * 2009 Sales: $4.5 Billion <ref>http://www.reuters.com/article/idUSN2223558720100222</ref> | ||
* Why You Should Care: Sales of Crestor are the fastest growing among the statins. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br /> | * Why You Should Care: Sales of Crestor are the fastest growing among the statins. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br /> | ||
| Line 97: | Line 97: | ||
* Unlike other statins, consuming grapefruit juice does not affect the PKs of rosuvastatin. <ref>PMID:9585793</ref> <ref>PMID: 11836106</ref> | * Unlike other statins, consuming grapefruit juice does not affect the PKs of rosuvastatin. <ref>PMID:9585793</ref> <ref>PMID: 11836106</ref> | ||
===The Jist=== | ===The Jist=== | ||
The statins | The statins are generally viewed as very safe and have been proven effective over the past 15 years. Rosuvastatin is the newest major blockbuster statin and was designed to be taken at lower levels than other statins. Recent studies have indicated rosuvastatin can reduce the likely hood of myocardial infarction and stroke, although this has been refuted by some studies. Truth be told, with major statins like Lipitor coming off patent in the next year or two, pharmaceutical companies are looking for new diseases that can be treated by still-patented statins like Rosuvastatin (Patent expires in 2016). With $4 billion in sales per year and Lipitor going off patent in 2011, resulting in a dramatic price drop in statins as generics flood the market, proving that Rosuvastatin reduces heart attacks, etc. would be worth many billions of dollars. It remains to be seen whether the potential reduction in heart ailments while taking Rosuvastatin, if it exists, can be proven with statistical significance. | ||
===References=== | ===References=== | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||
__NOTOC__ | __NOTOC__ | ||